Myxedema Coma Market Size & Share, by Route of Administration (Oral, Injectable); Indication (Hypothyroidism, Hypocortisolemia, Hypoventilation, Hypoglycemia, Hypotension); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies); Drug Class (Synthetic, Natural) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

  • Report ID: 4897
  • Published Date: May 02, 2023
  • Report Format: PDF, PPT

Companies Dominating the Myxedema Coma Landscape

    • AbbVie Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Merck & Co., Inc.
    • Pfizer Inc.
    • GSK plc.
    • Sanofi Global
    • Mylan N.V.
    • Teva Pharmaceutical Industries Ltd.
    • Novartis AG
    • Lannett Company, Inc.
    • Zydus Lifesciences

Browse Key Market Insights with Data Illustration:


In The News

  • Mylan N.V received FDA approval for Ermeza (levothyroxine), which is available in oral dose formulations such as generic tablet and capsule forms, and can be used as a supplemental treatment to surgery and radioiodine therapy or as a replacement therapy for congenital or acquired hypothyroidism in adult and pediatric patients.
  • Zydus Lifesciences got approval from the US Food and Drug Administration (USFDA) for marketing the Levothyroxine Sodium Injection which is used to treat myxedema coma or extreme hypothyroidism.

Author Credits:  Radhika Gupta, Shivam Bhutani

  • Report ID: 4897
  • Published Date: May 02, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Higher prevalence of type 1 diabetes and the growing geriatric population are the major factors driving the growth of the market.

The market size of myxedema coma is anticipated to attain a CAGR of 4% over the forecast period, i.e., 2023-2035.

The major players in the market are Merck & Co., Inc., Pfizer Inc., GSK plc., Sanofi Global, Mylan N.V., Teva Pharmaceutical Industries Ltd., Novartis AG, Lannett Company, Inc., Zydus Lifesciences.

The oral segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.

: The major players in the market are AbbVie Inc., Merck & Co., Inc., Pfizer Inc., GSK plc., and more.

The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.
Inquiry Before Buying Request Free Sample

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying